One of the hallmarks of good medical care is the ability to measure progress objectively. When a child is treated for diabetes, we follow hemoglobin A1c. When we manage hypertension, we monitor blood pressure. Across medicine, clinicians combine their judgment with standardized measures to understand whether treatment is helping and whether adjustments are needed.
Autism care has historically relied on different approaches. Clinical expertise, caregiver observations, and individualized treatment goals remain essential, but objective, standardized measures of developmental progress have been much more limited. That is one reason I found the Centers for Medicare & Medicaid Services’ newly released State Medicaid & CHIP Applied Behavior Analysis Toolkit so noteworthy.
Although the toolkit is guidance rather than regulation, CMS has outlined a framework that emphasizes measurable outcomes, periodic reassessment, and documentation of meaningful functional progress throughout treatment. For providers, health plans, and state Medicaid agencies, it offers insight into how accountability and quality measurement in autism services may continue to evolve.
A Greater Emphasis on Measuring Progress
The toolkit recommends that individualized treatment plans include baseline assessment results, measurable goals, regular reassessment, and anticipated treatment timelines. It also highlights examples from states that require updated progress information during reauthorization, including the use of objective data alongside clinical documentation.
These recommendations reflect a broader movement throughout healthcare. As payment models increasingly focus on value and outcomes, demonstrating progress becomes as important as documenting the services delivered.
For autism providers, that means asking an important question throughout treatment, not just at the beginning:
How do we know a child is making meaningful developmental progress?
Clinical Judgment Remains Essential
Anyone who has cared for children with autism understands that progress is rarely captured by a single measure. Clinician observations matter. Parent perspectives matter. Individualized goals matter because every child develops differently.
At the same time, each of these perspectives has limitations when considered in isolation. Providers naturally document the goals they are working toward. Parents observe meaningful changes in everyday life that clinicians may never see. Both are valuable, but each reflects a different point of view.
That is why I was encouraged to see the toolkit recommend that states consider including at least one standardized outcome assessment instrument rather than relying exclusively on provider-developed measures. Standardized assessments can complement clinical judgment by providing a consistent reference point over time.
The goal is not to replace clinical expertise. It is to strengthen it.
What Objective Measurement Can Contribute
Throughout medicine, objective measurements help clinicians recognize when treatment is working, when it needs to be adjusted, and when patients are ready to transition to a different level of care.
Autism care should be no different.
Objective developmental measurement has the potential to help clinicians better understand change over time, facilitate conversations with families, and support more consistent communication with payers. Standardized data can also help providers demonstrate treatment effectiveness while informing quality improvement efforts across organizations.
CMS appears to recognize that measurement science continues to evolve. The toolkit notes that the agency is following innovative technologies and data analytic tools that may assist clinicians. Importantly, it does not endorse any specific technology or suggest that objective measurement should replace comprehensive clinical evaluation.
I believe that distinction is critical.
Technology should support clinicians, not substitute for them. Comprehensive assessment, thoughtful clinical interpretation, and individualized treatment planning will always remain central to high-quality autism care.
Why This Matters for Children and Families
At EarliPoint Health, where I serve as Chief Medical Officer, we have focused on developing objective developmental measures to complement clinical decision-making. Our FDA-cleared eye-tracking technology provides standardized measures of social visual engagement, language comprehension, and nonverbal learning in young children at risk for autism.
While I believe objective measurement represents an important advancement, the broader principle extends beyond any single technology.
Children deserve reliable ways to measure developmental progress over time. Families deserve clear information about how treatment is helping. Clinicians deserve tools that support evidence-based decision-making. Payers and policymakers deserve meaningful data that demonstrate outcomes while preserving individualized care.
Those goals are not in conflict. In fact, they reinforce one another.
Looking Ahead
One aspect of the CMS toolkit stood out to me more than any other: its emphasis on planning not only how treatment begins, but also how it progresses and ultimately transitions over time.
That requires ongoing measurement.
As autism care continues to evolve, I believe objective developmental measurement will become an increasingly important complement to clinical expertise, individualized goals, and family input. The question is not whether one source of information is sufficient. It is how we thoughtfully combine multiple sources of evidence to make the best possible decisions for each child.
Ultimately, that is what every clinician wants: the ability to understand whether treatment is making a meaningful difference and to use that knowledge to improve care.
